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The hepatitis B virus (HBV) genome forms a covalently closed circular DNA (cccDNA)
minichromosome that persists in the nucleus of virus-infected hepatocytes. HBV cccDNA
serves as the template for viral mRNA synthesis and is subject to epigenetic regulation
by several mechanisms, including DNA methylation and histone acetylation. Recently,
microRNAs (miRNAs), a class of small non-coding RNAs, were also directly connected
to the epigenetic machinery through a regulatory loop. Epigenetic modiﬁcations have
been shown to affect miRNA expression, and a sub-group of miRNAs (deﬁned as epi-
miRNAs) can directly target effectors of the epigenetic machinery. In this review, we
will summarize recent ﬁndings on the epigenetic mechanisms controlling HBV cccDNA
function, primarily focusing on the epi-miRNA functions operating in HBV replication.
Investigation of the epigenetic regulation of HBV replication may help to discover novel
potential therapeutic targets for drug development with the goal to eradicate the HBV
cccDNA pool in hepatocytes.
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INTRODUCTION
Hepatitis B virus (HBV) infection is a global health problem
that causes a wide spectrum of liver diseases, including acute or
chronic HBV infection. Acute HBV infections either resolve or
progress to chronicity. Chronic hepatitis B (CHB) is associated
with chronic hepatitis, cirrhosis, and hepatocellular carcinoma
(HCC; McMahon, 2009). It is estimated that more than 350 mil-
lionpatientsworldwide are chronically infectedwithHBV,with the
majority of these patients living in the Asia-Paciﬁc region. More
than one million deaths occur each year as a direct consequence
of CHB (Dienstag, 2008). Medical intervention using antiviral
nucleoside/nucleotide analogs and interferon (IFN) was estab-
lished to treat chronically infected patients (Pardo et al., 2007).
However, currently available therapies do not lead to the termi-
nation of HBV infection in the majority of patients (Mailliard
and Gollan, 2006). There is a consensus that the improved under-
standing of the HBV–host interaction is a prerequisite for new
antiviral therapeutic strategies. Recently, many aspects pertaining
to the epigenetic mechanisms responsible for viral persistence and
clearance during HBV replication have been addressed, including
methylation of viral DNA, acetylation of histone complexes, and
microRNA (miRNA) regulation. These topics are described in this
review.
HBV cccDNA STRUCTURE AND ITS ROLE IN HBV INFECTION
Hepatitis B virus is the prototype member of the family Hepad-
naviridae and has a partially double-stranded DNA genome of
Abbreviations: 5-AzaC, 5-azacytidine; cccDNA, covalently closed circular DNA;
CHB, chronic hepatitis B; DNMT, DNA methyltransferase; HBV, hepatitis B
virus; HCC, hepatocellular carcinoma; HDAC, histone deacetylase; IFN, interferon;
miRNA, microRNA; SIRT1, sirtuin 1; TSA, trichostatin A.
approximately 3.2 kb in length. The viral genome harbors seven
open reading frames, coding for the viral polymerase, HBV core,
and e antigens (HBcAg and HBeAg); the regulatory HBx protein;
and the preS/S gene encoding the three surface antigens (LHBsAg,
MHBsAg, and SHBsAg). The genome also contains a number of
regulatory elements (Seeger and Mason, 2000). The entry of HBV
virions is likely initiated through a non-speciﬁc interaction with
negatively charged glycans at the surface of hepatocytes (Schulze
et al., 2007; Bremer et al., 2009) followed by speciﬁc binding to the
sodium-taurocholate cotransporting polypeptide (NTCP) recep-
tor by a speciﬁc sequence (2-48aa) located in the preS1 domain
of the LHBsAg protein (Yan et al., 2012). After uncoating, the
HBV capsid is transported by the cellularmachinery to the nuclear
pore. The open circular form of HBV genomic DNA is then con-
verted to a covalently closed circular DNA (cccDNA) molecule
in the nucleus. This process requires that the covalently attached
viral polymerase is removed from the negative DNA strand by a
proteinase and that the positive strand DNA is completed by the
cellular replicativemachinery so that itmatches the negative strand
to covalently join the two ends to form a circular, supercoiled
molecule (Gao and Hu, 2007).
In the nucleus,HBVcccDNA is incorporated into the host chro-
matin and exists as an individual minichromosome with a “beads-
on-a-string” structure, which is revealed by electron microscopy
(Bock et al., 1994; Newbold et al., 1995). This minichromosome
has been shown to consist of both histone and non-histone pro-
teins. By immunoblotting with HBcAg, the histone proteins H3
and H2B were the most prominent species, while lower levels of
H4, H2A, and H1 were also detectable (Bock et al., 2001). Using
the cccDNA-ChIP assay, the group of Massimo Levrero has con-
ﬁrmed the recruitment of the H3 and H4 histones along with the
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HBcAg andHBx proteins to the cccDNAminichromosome. Using
the same approach, several cellular transcription factors (CREB,
ATF, YY1, STAT1, and STAT2) and chromatin modifying enzymes
(PCAF, p300/CBP, HDAC1, SIRT1, and EZH2) have been shown
to bind to the cccDNA in human hepatoma cells containing repli-
cating HBV (Pollicino et al., 2006; Belloni et al., 2009, 2012). The
histone acetyltransferases (HATs) p300/CBP and PCAF and the
histone deacetylases (HDACs) HDAC1 and SIRTl were shown to
be recruited with different kinetics onto HBV cccDNA, implying
that HBV cccDNA-bound histones may be subjected to regulatory
post-translational modiﬁcations (Levrero et al., 2009).
Because cccDNA is the transcriptional template of the virus
(Quasdorff and Protzer, 2010), it is required for the maintenance
of HBV infection. Unlike HBV transcripts and replicative inter-
mediates, cccDNA is very stable in quiescent hepatocytes and is
responsible for the persistence of infection during the natural
course of chronic HBV infection and during prolonged antiviral
therapy (Werle-Lapostolle et al., 2004). The cccDNA may persist
for many years in the liver of patients, even after successful antivi-
ral treatment and reinforcement of immunologic control (Zoulim,
2005). Currently, little is known about the mechanism of HBV
cccDNA maintenance in the nuclei of hepatocytes. However, it
has been shown that the cccDNA can be eliminated when infected
hepatocytes are removed by immune cell-mediated killing or other
non-cytopathic mechanisms (Murray et al., 2005) and replaced by
cell turnover (Lutgehetmann et al., 2010).
REGULATION OF HBV cccDNA TRANSCRIPTION BY
EPIGENETIC MODIFICATION
HISTONE ACETYLATION AND METHYLATION
Recently, it was proposed that the functionality of HBV cccDNA
might be controlled by epigenetic mechanisms, regulating its
transcriptional activity and HBV replication. Histones and non-
histone proteins either bind directly to the cccDNA or are
indirectly recruited to viral minichromosomes through protein–
protein interactions. Thereby, the acetylation and deacetylation of
cccDNA-bound histonesmay regulate HBV transcription. Explor-
ing a ChIP assay using anti-acetylated-H3 or -H4 antibodies,
Pollicino et al. (2006) found that HBV replication is indeed regu-
lated by the acetylation status of H3/H4 histones bound to the viral
cccDNA, both in cell-based replication systems and in the liver of
chronically HBV infected patients. The co-recruitment of PCAF
and p300/CBP parallels viral replication in vitro, whereas HDAC1
recruitment onto theHBV cccDNA correlates with lowHBV repli-
cation in vitro and with low viremia in vivo. The importance of
epigenetic modiﬁcations of cccDNA-bound histones in the reg-
ulation of HBV replication is further conﬁrmed by experiments
exploring the class I and class III HDAC inhibitors trichostatin
A (TSA), valproate, and nicotinamide (NAM). These HDAC
inhibitors induce an evident increase of both cccDNA-bound
acetylatedH4 andHBV replication. Another study demonstrated a
similar role for the acetylation of cccDNA-bound histones, as well
as a role for methylation and phosphorylation of these proteins
(Gong et al., 2011).
A recent study demonstrated that in cultured hepatoma cells
with HBV replication and in mouse models with repopulated
human hepatocytes, administration of IFN-α resulted in the
active recruitment of the transcriptional corepressors HDAC1,
SIRT1, and polycomb repressor complexes 2 (EZH2 and YY1)
to HBV cccDNA as well as the hypoacetylation/hypermethylation
of cccDNA-bound histones. IFN-α treatment also reduced the
binding of the transcription factors STAT1 and STAT2 to the IFN-
sensitive response element on active cccDNA (Belloni et al., 2012).
These observations suggested that IFN-α could epigenetically reg-
ulate HBV replication, and the hypoacetylation/hypermethylation
of histones was associated with decreased replication of HBV. Fur-
thermore, it was shown that small molecules that inhibit p300 and
PCAF or activation of SIRT1/2 and EZH2 could induce an “active
epigenetic suppression” of the HBV cccDNA minichromosome to
suppress HBV replication (Palumbo et al., 2013).
HBV DNA METHYLATION
In addition to post-translational modiﬁcation of histones, methy-
lation of the CpG islands on HBV genomic DNA also contributes
to the regulation of HBV gene expression (Mogul et al., 2011;
Rivenbark et al., 2012). It has been shown that early integrated
HBVDNA ismethylated inHCC cells (Miller and Robinson, 1983;
Chen et al., 1988). The non-integrated HBV DNA (Vivekanandan
et al., 2008b) and cccDNA (Guo et al., 2009) could also be methy-
lated in liver tissues from patients. Currently, at least six CpG
islands have been identiﬁed in the HBV genome, including three
conventional regions overlapping the start site of the HBV S gene
(island 1), the region encompassing enhancer I and the X gene
promoter (island 2), and the Sp1 promoter and start codon of the
P gene (island 3; Zhang et al., 2013b). Methylation of CpG islands
1 and 2 was found in HBV DNA extracted from liver biopsies
fromCHB patients, suggesting that increasedmethylation of HBV
DNA may decrease the production of viral proteins (Vivekanan-
dan et al., 2008b). The hypermethylation of island 2was correlated
with low levels or absence of HBsAg production (Vivekanandan
et al., 2008a), as well as reduced HBeAg expression (Guo et al.,
2009). It was shown that individuals with occult HBV infection,
which is characterized by the persistence of HBV DNA in the liver
of individuals who test negative for theHBsAg, had a higher degree
of methylation in island 2 compared to non-occult CHB patients
(Vivekanandan et al., 2008a). Another study with a cohort of cir-
rhosis patients did not ﬁnd an association between themethylation
status of HBV cccDNA and HBsAg expression in liver tissues, but
conﬁrmed that a higher methylation density was associated with
lower viral load, lower RNA copies per cccDNA, and lower virion
productivity (Kim et al., 2011).
Consistent with these ﬁndings, transfection of methylatedHBV
DNA in HepG2 cells resulted in reduced HBV mRNA levels,
decreased intracellular HBsAg and core HBcAg expression, and
decreased secretion of HBV viral proteins into cell supernatants.
Furthermore, an in vitro equivalent of cccDNA showed decreased
viral protein production in HepG2 cells after DNA methyla-
tion (Vivekanandan et al., 2009). After transfection of HBV DNA
into HepG2 cells, an inverse relationship between methylated
HBV DNA and viral mRNA levels was observed in dependence
on the upregulation of host DNA methyltransferase (DNMT).
Cotransfection with DNMT3a and HBV DNA was associated
with decreased production of HBsAg and HBeAg, as well as host
proteins implicated in carcinogenesis (Vivekanandan et al., 2010).
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These data from cell culture experiments suggest that HBV DNA
methylation is associated with down regulation of viral protein
production.
INTERPLAY BETWEEN HBV, miRNAs, AND THE EPIGENETIC
MACHINERY
miRNAs PLAY A PIVOTAL ROLE IN THE EPIGENETIC REGULATION
NETWORK
MicroRNAs are approximately 22 nucleotide-long non-coding
RNAs that are emerging as key players in regulating gene expres-
sion in eukaryotes, inﬂuencing various biological processes such as
development, infection, immunity, and carcinogenesis (Ambros,
2004). The biogenesis and mechanisms of action of these tiny
but potent molecules have been described in detail (Bartel, 2004).
Brieﬂy, miRNAs are transcribed from the host genome and gener-
ated by Drosha- and Dicer-mediated enzymatic cleavage. Mature
miRNAs are engaged in either translational arrest or degradation
of targeted transcripts through imperfect base pairing with the
3′-untranslated region (UTR) or the coding region of the tar-
get transcripts. Currently, more than 2000 miRNAs have been
identiﬁed in human organs (Grifﬁths-Jones et al., 2008). The
expressionproﬁles of thesemiRNAs indifferent cells or tissuesmay
exhibit temporal or tissue-speciﬁc patterns (Skalsky and Cullen,
2010).
Many studies have shown that a set of miRNAs play a piv-
otal role in the epigenetic regulation network (Chuang and Jones,
2007; Iorio et al., 2010). Epigenetic modiﬁcations, such as pro-
motermethylation or histone acetylation, have been demonstrated
to affect miRNA expression and are potentially responsible for
the aberrant miRNA regulation observed in cancer (Baer et al.,
2013). Along with the epigenetic regulation of miRNA expression,
many miRNAs themselves can regulate the expression of compo-
nents of the epigenetic machinery, creating a highly controlled
feedback mechanism. A number of the miRNAs related to epi-
genetic regulation were deﬁned as so-called “epi-miRNAs.” For
example, DNMT1 overexpression was responsible for the hyper-
methylation of the miR-148a and miR-152 promoters. As a direct
target of miR-148a and miR-152, DNMT1 was inversely related
to the expression levels of miR-148a and miR-152 (Chen et al.,
2013). Similarly, miR-1 and miR-449a, which could be induced
by 5-AzaC/TSA treatment (Datta et al., 2008) or by HDAC1-3
knock down (Buurman et al., 2012) in HCC cells, directly targeted
HDAC4 (Chen et al., 2006) and HDAC1 (Noonan et al., 2009),
respectively.
HBV INFECTION AFFECTS miRNA EXPRESSION
Although the viral miRNAs encoded by HBV have not been veri-
ﬁed, the products of HBV were shown to alter miRNA expression
proﬁles. In chronic HBV infection or HBV-related HCC, the
miRNA proﬁles in liver tissue or serum levels from numerous
studies are controversial and complicated (Ura et al., 2009; Hou
et al., 2011; Liu et al., 2011; Wang et al., 2012b). For instance, it
was reported that subviral HBsAg circulating in the blood of HBV
carriers could carry liver-speciﬁc miRNAs (miR-27a, miR-30b,
miR-122, miR-126, and miR-145) as well as immune regulatory
miRNAs (miR-106b and miR-223) that were involved in hepato-
carcinogenesis and HBV persistence (Novellino et al., 2012). In
another study, three miRNAs (miR-122, miR-22, and miR-99a)
were upregulated at least 1.5-fold in the sera of HBV-infected
patients (Hayes et al., 2012). The highly liver-enriched, abundantly
expressed miR-122 was consistently upregulated in HBV infected
patients, andmiR-145 could be used as a candidate tumor suppres-
sivemiRNA in the early steps of HBV-related hepatocarcinogenesis
(Gao et al., 2011).
Recently, molecular studies have revealed that the HBx protein,
which is essential for virus replication in vivo, induced epige-
netic changes, including aberrations in DNAmethylation, histone
modiﬁcations, and miRNA expression. HBx expression has been
found to be associated with alterations in the host miRNA pro-
ﬁle through different epigenetic mechanisms (Tian et al., 2013).
MiRNAs upregulated by HBx include miRNA-29a and miR-143
(Zhang et al., 2009; Kong et al., 2011). HBx-downregulated miR-
NAs include miR-101, miR-122, miR-132, miR-148a, miR-152,
let-7, and the miR-16 family (Huang et al., 2010; Wang et al.,
2010; Wu et al., 2011; Song et al., 2013; Wei et al., 2013a,b; Xu
et al., 2013). In addition, HBx was shown to activate HBV tran-
scription through opposition to the protein phosphatase 1 and
HDAC1 complex on the HBV cccDNA (Cougot et al., 2012), or
down-regulate DNMT3A expression through miR-101 induction
(Wei et al., 2013b). Loss of HBx reduced recruitment of p300,
caused rapid hypoacetylation of the cccDNA-bound histones and
increased early recruitment of SIRT1 and HDAC1, accompanied
by lower HBV replication (Belloni et al., 2009).
CELLULAR miRNAs INHIBIT HBV REPLICATION BY DIRECT BINDING
As HBV produces different transcripts during its life cycle, the
transcripts are proposed to be targeted by cellular miRNAs. In
a screen for cellular miRNAs affecting HBV replication, Zhang
et al. (2010) employed a loss-of-function approach by trans-
fecting antagomirs targeting 328 human miRNAs into HepG2
cells. Two miRNAs, miR-199a-3p and miR-210, were shown to
suppress HBsAg expression. The direct effect of these two miR-
NAs on HBV RNA transcripts was validated by GFP reporter
assay (Zhang et al., 2010). In addition, Russo’s group found
that miR-125a-5p is able to interfere with HBsAg expression,
thus reducing the amount of secreted HBsAg (Potenza et al.,
2011). Recently, many cancer-related miRNAs, including miR-
15a/miR-16-1 (Wang et al., 2013a), the miR-17-92 cluster (Jung
et al., 2013), and miR-224 (Scisciani et al., 2011), were shown
to target HBV mRNAs directly by luciferase reporter assay and
inhibit HBV replication (summarized in Figure 1). Notably, the
expression of these miRNAs was also linked to epigenetic reg-
ulation, as well as to promoter methylation (Dakhlallah et al.,
2013) and histone acetylation (Zhang et al., 2013a; Wang et al.,
2013b).
CELLULAR miRNAs REGULATE HBV REPLICATION INDIRECTLY
In addition to direct targeting, some cellular miRNAs, includ-
ing epi-miRNAs, were found to be capable of inhibiting or
stimulating HBV replication by indirectly regulating cellular tran-
scription factors. It was shown that the transcription of HBV
cccDNA was tightly regulated by a number of liver-enriched
transcription factors and nuclear receptors through the recog-
nition of HBV promoter/enhancer elements (Quasdorff and
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FIGURE 1 | Summary of cellular miRNAs effect on HBV replication. HBV
DNA could be integrated into host genome or form cccDNA minichromosome
in the hepatocytes nucleus. It serves as the temple for viral transcription, viral
DNA, and antigens production. The miRNAs which regulate HBV replication
through epigenetic mechanism, transcription factors regulation, immune
regulation, and direct targeting viral transcripts were indicated.
Protzer, 2010). miR-122 may exert its effect on HBV indirectly
via downregulation of its target cyclin G1, thus interrupting
the interaction between cyclin G1 and p53 and abrogating p53-
mediated inhibition of HBV replication (Wang et al., 2012a).
miR-372 and -373 are upregulated in HBV-infected liver tis-
sues and promote HBV gene expression through a pathway
involving the transcription factor nuclear factor I/B (Guo et al.,
2011). The higher expression of miR-501 in HCC tissues could
enhance HBV replication partially by targeting HBXIP (Jin et al.,
2013). In contrast, miR-141 signiﬁcantly suppresses HBV expres-
sion and replication in HepG2 cells. Bioinformatic analysis
and experimental assays indicate that peroxisome proliferator-
activated receptor alpha is a relevant target of miR-141 during
this process (Hu et al., 2013). For immune-related miRNAs,
miR-155 enhances innate antiviral immunity by promoting the
Janus kinase/signal transducer and activator of transcription
(JAK/STAT) signaling pathway through the targeting of SOCS1,
mildly inhibiting HBV infection in human hepatoma cells (Su
et al., 2011).
By screening a set of cellularmiRNAs, our group found that epi-
genetically regulated miR-1 over-expression resulted in a marked
increase in HBV replication, accompanied with upregulated HBV
transcription, antigen expression, and progeny secretion. HDAC4,
the cellular target of miR-1, was able to suppress HBV replication.
The expression of nuclear receptor farnesoid X receptor alpha
(FXRA) was increased by miR-1, leading to the enhanced tran-
scriptional activity of the HBV core promoter (Zhang et al., 2011).
Furthermore, another epi-miRNA that targets HDAC1,miR-449a,
had an even higher capacity for enhancing HBV replication but
a lower level of induction of FXRA (Zhang et al., unpublished
data). Additionally, both of these two deﬁned epi-miRNAs could
inhibit the G1/S cell cycle transition and promote cell differenti-
ation by increasing the expression of hepatocyte-speciﬁc factors,
which may be beneﬁcial for HBV replication (Zhang et al., 2011).
Collectively, host epi-miRNAs can modulate HBV replication by
regulating cellular epigenetic factors or speciﬁc transcription fac-
tors that directly bind to the HBV cccDNA minichromosome
(summarized in Figure 1).
CONCLUSION AND PERSPECTIVE
In this review, we summarize the available information about
the epigenetic mechanisms involved in the regulation of HBV
cccDNA function. Notably, miRNAs could be considered part of
a multilevel regulatory mechanism aimed to precisely modulate
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HBV replication and gene expression, likely in the response to the
changing hepatic microenvironment. Considerably, many cellular
miRNAs indirectly inﬂuence the HBV life cycle by regulating the
expression of relevant cellular proteins and may play important
roles in hepatitis B pathogenesis. Future studies need to be per-
formed to elucidate the regulatory loop involvingmiRNAs and the
cccDNA epigenetic machinery and certainly to investigate how to
translate these ﬁndings into clinical applications.
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